All In MedTech

Device Trial Radar · NCT07362160

Clear Orthodontic Expander Versus Hyrax

Evaluating the Clinical Performance of a Novel Clear Orthodontic Expander Versus Hyrax: A Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Nov 1, 2026

Study completion Feb 1, 2027

Sponsor

Lead sponsor
University of BaghdadAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 10 years, up to 14 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the effectiveness of a clear expander fabricated from 2-mm biocompatible polyethylene terephthalate glycol (PETG) thermoforming material integrated with an expansion screw in achieving dental and skeletal expansion in adolescent patients, compared with the conventional Hyrax expander.

Conditions

  • Malocclusion
  • Narrow Maxilla

Interventions

  • New clear expanderDevice

    All patients with a clear expander will be instructed to wear the appliance 24 hours a day, except during eating and cleaning. The expander will be activated twice daily (0.2 mm per turn). Patients will be provided with an instruction brochure and advised to use a reminder to ensure compliance. The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cusps to overcome the expected relapse due to the elasticity of the palatal soft tissue.

  • Hyrax expanderDevice

    The activation protocol for the Hyrax expander will be the same in all patients, twice daily (0.2 mm per turn). The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cusps to overcome the expected relapse due to the elasticity of the palatal soft tissue.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CBCT evaluationTime frame: pre-treatment (T0) and immediately post-treatment (T1) around one to two months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Baghdad/Collage of Dentistry

    Baghdad, Al-Rusafa, Bab Al-moadham, Iraq · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.